Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.
Technology platformRNA therapeutics have emerged as a new modality for combating serious infections. Find out more about the science behind our next-generation RNA platform.
ScienceOur Managing Director Tim Sparey will take our self-amplifying RNA platform (saRNA) on the road to join #BiotechShowcase, one of the biggest #biotech and #lifesciences investor and networking conferences. Contact info@vaxequity.com to connect! https://t.co/cXQBuvEvWd
Tim Sparey will be attending the @LSXLeaders #InvestivalShowcase, and together with Rob Barber they will be at the Jefferies London Healthcare Conference, to seek out like-minded companies interested in advancing the self-amplifying RNA platform (saRNA) space. https://t.co/eAJK5p9gcq
We have recieved your message and will get back to your shortly.
